Search Within

Paul K Paik

Formats
  1. Meeting Abstract (168)
  2. Journal Article (85)
  3. Review (5)
  4. Book Section (1)
Groups
  1. Department of Medicine (259)
  2. Solid Tumor Oncology Division (259)
  3. Thoracic Oncology (259)
  4. GSK Faculty (77)
  5. Department of Pathology and Laboratory Medicine (73)
  6. Human Oncology and Pathogenesis Program (55)

More Groups

People
  1. Mark Kris (55)
  2. Marc Ladanyi (47)
  3. Gregory Riely (42)
  4. Natasha Rekhtman (41)
  5. Charles Rudin (40)
  6. Jamie Chaft (34)

More People

Years
  1. 2025 (9)
  2. 2024 (15)
  3. 2023 (32)
  4. 2022 (39)
  5. 2021 (34)
  6. 2020 (18)

More Years

Publications
  1. Journal of Thoracic Oncology (60)
  2. Journal of Clinical Oncology (49)
  3. Annals of Oncology (34)
  4. Clinical Cancer Research (13)
  5. International Journal of Radiation Oncology, Biology, Physics (11)
  6. Clinical Lung Cancer (6)

More Publications

Publishers
  1. Elsevier Inc. (82)
  2. American Society of Clinical Oncology (56)
  3. Oxford University Press (38)
  4. American Association for Cancer Research (23)
  5. Wiley Blackwell (12)
  6. Nature Publishing Group (11)

More Publishers

Results (259)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Tepotinib activity in brain metastases (BM): Preclinical models and clinical data from MET exon 14 (METex14) skipping NSCLC
    Meeting Abstract

    Viteri, S.; Mazieres, J.; Veillon, R.; Felip, E.; Le, X.; Garassino, M.; Stanton, T.; Morise, M.; Lee, J. S.; Matsumoto, S.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Tepotinib exposure-response analyses of safety and efficacy in patients with solid tumors
    Meeting Abstract

    Xiong, W.; Hietala, S.; Nyberg, J.; Papasouliotis, O.; Anziano, R.; Berghoff, K.; Johne, A.; Girard, P.; Strotmann, R.; Paik, P.
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Tepotinib in patients with advanced NSCLC with MET exon 14 (METex14) skipping: Overall efficacy results from VISION cohort A
    Meeting Abstract

    Mazieres, J.; Paik, P.; Felip, E.; Veillon, R.; Sakai, H.; Cortot, A.; Viteri, S.; Garassino, M.; Van Meerbeeck, J.; Raskin, J.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Liquid biopsy to detect MET alterations in patients with advanced NSCLC: Biomarker analysis from the VISION study
    Meeting Abstract

    Le, X.; Kowalski, D.; Cho, B. C.; Conte, P.; Felip, E.; Garassino, M.; Viteri, S.; Chang, G. C.; Richart, J.; Paz-Ares, L.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in patients with NSCLC harboring MET exon 14 skipping (METex14) treated with tepotinib
    Meeting Abstract

    Garassino, M.; Le, X.; Kowalski, D.; Migliorino, M.; Senellert, H.; Pradera, J.; Walling, R.; Kato, T.; Thomas, M.; Smit, E.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
    Journal Article

    Valero, C.; Lee, M.; Hoen, D.; Weiss, K.; Kelly, D. W.; Adusumilli, P. S.; Paik, P. K.; Plitas, G.; Ladanyi, M.; Postow, M. A.; more...
    Nature Communications (2021)

    Fulltext@MSK | Save
  • MET exon 14-altered lung cancers and MET inhibitor resistance
    Journal Article

    Guo, R.; Offin, M.; Brannon, A. R.; Chang, J.; Chow, A.; Delasos, L.; Girshman, J.; Wilkins, O.; McCarthy, C. G.; Makhnin, A.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Phase 1 trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in patients with advanced NSCLC (NCI 10327): Rationale and study design
    Journal Article

    Riess, J. W.; Frankel, P.; Shackelford, D.; Dunphy, M.; Badawi, R. D.; Nardo, L.; Cherry, S. R.; Lanza, I.; Reid, J.; Gonsalves, W. I.; more...
    Clinical Lung Cancer (2021)

    Fulltext@MSK | Save
  • Genomic analyses for predictors of response to chemoradiation in stage III non-small cell lung cancer
    Journal Article

    Luo, L. Y.; Samstein, R. M.; Dick-Godfrey, R.; Sidiqi, B.; Wang, C.; Oro, F.; Sonnick, M.; Paik, P. K.; Chaft, J. E.; Shaverdian, N.; more...
    Advances in Radiation Oncology (2021)

    Fulltext@MSK | Save
  • A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC)
    Meeting Abstract

    Skoulidis, F.; Neal, J. W.; Akerley, W. L.; Paik, P. K.; Papagiannakopoulos, T.; Reckamp, K. L.; Riess, J. W.; Jenkins, Y.; Holland, S.; Parlati, F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save